Two years of experience in the treatment of status epilepticus with intravenous levetiracetam.
Since its introduction in 2006, 43 patients with various forms of status epilepticus (SE) have been treated with the intravenous formulation of levetiracetam (LEV) in our clinic. After ineffective treatment with benzodiazepines, intravenous LEV was administered as a short infusion (nonconvulsive and subtle SE) at a dose of 1000 or 2000 mg. In cases of convulsive SE, a fractionated injection of 1000 or 2000 mg was used. When the results for both are combined, SE could be terminated in 19 of 43 patients. Intravenous LEV was more effective in simple focal SE (3/5), complex focal SE (11/18) and myoclonic status (2/2) than in nonconvulsive (2/8) and subtle (1/2) SE. In no case was (secondarily) generalized convulsive status epilepticus (0/8) terminated. Intravenous LEV was also well-tolerated when injected in fractionated form. No severe adverse reactions were observed. As a result of this investigation, intravenous LEV in moderate doses may represent an efficacious and well-tolerated alternative for the treatment of focal (simple and complex focal) and myoclonic SE. Further investigations are needed to confirm this assumption as the patient numbers are quite low.
Eue
S
S
Department of Neurology, Klinikum Bernburg gGmbH, Kustrenaer Strasse 98, Bernburg, Germany. dr.eue.neuro@klinikum-bernburg.de
Grumbt
M
M
Müller
M
M
Schulze
A
A
D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000927:Anticonvulsants / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002561:Cerebrovascular Disorders / Q000150:complications; D004831:Epilepsies, Myoclonic / Q000150:complications / Q000188:drug therapy; D004828:Epilepsies, Partial / Q000150:complications / Q000188:drug therapy; D005260:Female; D005858:Germany; D006801:Humans; D007275:Injections, Intravenous; D000077287:Levetiracetam; D008297:Male; D008875:Middle Aged; D010889:Piracetam / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013226:Status Epilepticus / Q000145:classification / Q000188:drug therapy* / Q000209:etiology
D000927:Anticonvulsants; D000077287:Levetiracetam; D010889:Piracetam